Active Biotech Q3 2024: Rights Issue Funds Laquinimod - Redeye

Redeye comments on Active Biotech's Q3 report. During the quarter, Active Biotech reported laquinimod concentrations in the vitreous segment of the eye and a rights issue. The rights issue can fund the company through the completion of the laquinimod's biodistribution study in 2025, which may position it for a licensing deal.

Länk till analysen i sin helhet: https://www.redeye.se/research/1045069/active-biotech-q3-2024-rights-issue-funds-2025?utm_source=finwire&utm_medium=RSS